Supra-annular mounting
Facilitates circularity and maximizes leaflet coaptation for lower gradients and reduced workload on the ventricle.Nitinol frame
Distributes mechanical forces to reduce leaflet stress, provide a larger effective orifice area, and minimize patient-prosthesis mismatch (PPM).External tissue wrap
Increases surface contact with native anatomy to reduce the risk of paravalvular leak (PVL).Four-time larger windows
Four-time larger windows Intended to enable coronary access with the Evolut™ FX+ TAVR.Fundamental differences in design exist among TAVR devices. Because women typically have smaller annuli than men, they require a valve that provides the largest area of blood flow to maximize valve performance.8
Supra-annular |Self-expanding
Intra-annular |Balloon-expandable
TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.
™* Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
† Evolut TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.
‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance for Evolut compared to SAPIEN and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.8
§ Better blood flow, or "near-normal transvalvular flow" means that your new heart is operating well and the gradient across your valve is < 20 mmHg%